|
|
|
27.05.26 - 13:09
|
Teva Pharmaceuticals Commits to Veeva Vault CRM (PR Newswire)
|
|
|
Agentic CRM with industry-specific AI for deeper customer engagement PLEASANTON, Calif., May 27, 2026 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) today announced that Teva Pharmaceuticals has committed to Veeva Vault CRM globally. "We are excited to expand our strategic partnership with......
|
|
|
|
|
|
|
|
|
|
|
|
|
19.05.26 - 14:33
|
Vistagen Appoints Angel S. Angelov, MD, MBA, as Chief Medical Officer (Business Wire)
|
|
|
Dr. Angelov brings extensive industry experience across multiple therapeutic areasSOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today announced the appointment of Angel S. Angelov, MD, MBA, as Chief Medical Officer (CMO), effective May 18, 2026.
"We are pleased to welcome Dr. Angelov to the Vistagen team,” said President and Chief Executive Officer of Vistagen, Shawn Singh. “His two decades of leadership across clinical development and medical affairs, including roles at Karuna, Neurocrine, Novartis, and Teva, will be instrumental as we work to improve suboptimal standards of care in our targeted therapeutic areas.”
Dr. Angelov most recently served as CMO at Theranica, a neuromodulation therapeutics company. Previously, Dr. Angelov served as Managing Director at ANG Holding, a...
|
|
|
|
|
|
|
|
|
|
|
18.05.26 - 14:03
|
Teva Study Finds Only 23% of Younger Adults with Mood Disorders and Tardive Dyskinesia (TD) Symptoms Are Formally Diagnosed with TD Despite Widespread Impact (GlobeNewswire EN)
|
|
|
PARSIPPANY, N.J. and TEL AVIV, Israel, May 18, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced new data from the ongoing, real-world IMPACT-TD Registry, highlighting a significant gap in diagnosing tardive dyskinesia (TD) in patients with underlying mood disorders. While the findings demonstrate that most patients across all age groups experience multidimensional impact from the condition, young adults (aged 18-29, n=13) had the lowest rate of formal diagnosis (23%) despite having one of the highest rates of personal impact (85%). The data were presented at the 2026 American Psychiatric Association Annual Meeting, taking place May 16 – 20, 2026 in San Francisco, California....
|
|
|
|
|
15.05.26 - 16:03
|
Carella Byrne Cecchi Brody Agnello, P.C. Announce a Class Action Settlement If You Paid for, Purchased, or Provided Reimbursement For a Drug Which Contained Metformin From July 20, 2015 through June 2, 2020 (PR Newswire)
|
|
|
ROSELAND, N.J., May 15, 2026 /PRNewswire/ -- Legal Notice Did You Purchase, Pay for, or Provide Reimbursement for a Drug that Contained Metformin? You Could Get Money from $5.55 Million in Settlements. There are Settlements in a class action lawsuit with Teva Pharmaceuticals USA, Inc.;......
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
